Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
about
Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapiesRecent advances in cancer stem/progenitor cell research: therapeutic implications for overcoming resistance to the most aggressive cancers.Imatinib-induced fatal acute liver failureIdentification of CD25 as STAT5-Dependent Growth Regulator of Leukemic Stem Cells in Ph+ CML.Targeting of cancer stem/progenitor cells plus stem cell-based therapies: the ultimate hope for treating and curing aggressive and recurrent cancers.Why doesn't imatinib cure chronic myeloid leukemia?DPPIV (CD26) as a novel stem cell marker in Ph+ chronic myeloid leukaemia.Expression of CD25 on leukemic stem cells in BCR-ABL1+ CML: Potential diagnostic value and functional implications.The difficulties in cancer treatment.Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents.Cell chip array for microfluidic proteomics enabling rapid in situ assessment of intracellular protein phosphorylation.Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches.Structural identification of imatinib cyanide adducts by mass spectrometry and elucidation of bioactivation pathway.Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.Intracellular protein trafficking kinetics in chronic myeloid leukemia stem cells using a microfluidic platform.Focal adhesion kinase is required for β-catenin-induced mobilization of epidermal stem cells.Staurosporine induces megakaryocytic differentiation through the upregulation of JAK/Stat3 signaling pathway.
P2860
Q33730375-0D98B614-8EEA-4481-871C-C0171D14B099Q35459525-520B4527-56D5-43BD-A6B3-4A1BB4831548Q36178243-546A8F5B-DAA6-488A-8A08-E96AEB6D9A9BQ36755221-87A2F24C-FAC2-4FC9-9994-BF875C387CFBQ37144023-344839D1-3CED-4AE2-96F3-F8D2F80E639EQ37685843-7BD16CD0-2DBC-4DA9-91AE-857092815D1EQ38265115-91629203-9F54-44FC-8540-17693101DBC1Q38812117-890C15CB-0CE8-4EE6-89B8-447DF23297FDQ39709531-AF9A0F1E-4939-48B3-A270-62A8F611BD9EQ40054238-B65EBF63-5777-4467-8767-624AA3FD03A8Q42752208-B67665C5-8DC0-40F7-96BF-E70B6FE69A49Q43078241-F615E337-2DA1-417D-A6F0-D19E7D15F3DAQ44430233-8280C5AB-D098-406F-AEBC-BFCB3F6686DCQ48010780-D638B8CB-B1BD-4C93-B3CA-BAABEB326234Q50123249-AC5BB237-9E35-49FF-BB6B-3F4917BFB77BQ51541983-6FB9BB89-6814-4BC2-B558-CEC3B7095B8AQ54484446-5F466AC7-6B59-426A-999D-1A1B30139DE0Q54611989-A92F3643-3F69-4F54-88CC-6129BF514B3B
P2860
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@ast
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@en
type
label
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@ast
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@en
altLabel
Evolving molecular therapy for chronic myeloid leukaemia—are we on target?
@en
prefLabel
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@ast
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@en
P2860
P50
P1433
P1476
Evolving molecular therapy for chronic myeloid leukaemia--are we on target?
@en
P2860
P304
P356
10.1080/10245330500234195
P577
2005-10-01T00:00:00Z